Testosterone Replacement Therapy Market Report 2025

The testosterone replacement therapy market size has grown steadily in recent years. It will grow from $2.04 billion in 2024 to $2.1 billion in 2025 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to rising incidence of hypogonadism, increased life expectancy, changing lifestyles, prevalence of diabetes and metabolic syndrome, patient preference for non-invasive therapies, growing male infertility concerns.

The testosterone replacement therapy market size is expected to see steady growth in the next few years. It will grow to $2.28 billion in 2029 at a compound annual growth rate (CAGR) of 2.1%. The growth in the forecast period can be attributed to precision medicine approaches, increasing male wellness market, regulatory support, globalization of health services, health and fitness trends, changing societal attitudes. Major trends in the forecast period include innovations in delivery systems, telemedicine and remote monitoring, customized treatment plans, nutritional and lifestyle approaches, research on combination therapies.

The testosterone replacement therapy market is anticipated to experience growth due to the increasing prevalence of testosterone deficiency, also known as hypogonadism. Hypogonadism is characterized by low testosterone levels, where the body is unable to produce an adequate amount of testosterone. Testosterone replacement therapy is employed to elevate testosterone levels within the physiological range, addressing the effects of hypogonadism and alleviating symptoms such as reduced libido, erectile dysfunction, depressed mood, anemia, muscle loss, and more. For instance, a report by Western Michigan Urological Associates in 2022 highlighted that approximately 13 million men in the United States, equivalent to 1 in 4 males over the age of 30, suffer from low testosterone levels. This underscores the growing incidence of testosterone deficiency, contributing to the expansion of the testosterone replacement therapy market.

The increasing geriatric population is projected to drive the growth of the testosterone replacement therapy market in the coming years. The geriatric population refers to older adults, typically defined as those aged 65 and above. Testosterone replacement therapy for this demographic aims to optimize hormonal balance, enhancing well-being and functional health among older individuals. For example, in October 2022, the World Health Organization, a Switzerland-based specialized health agency, reported that by 2030, 1 in 6 individuals globally will be 60 or older, with the number of elderly people expected to reach 2.1 billion by 2050. Consequently, the rising geriatric population is fueling the growth of the testosterone replacement therapy market.

Major companies in the testosterone replacement therapy (TRT) market are increasingly focusing on innovative delivery methods, such as oral formulations and telemedicine platforms, to offer men with low testosterone levels accessible and effective treatment options that improve overall health and well-being. PRIME is an oral testosterone replacement therapy (TRT) product designed to provide a non-invasive alternative to traditional injectable therapies for men with low testosterone levels. For example, in March 2024, Mangoceuticals Inc., a US-based company that specializes in men's health and wellness products, launched ‘PRIME’, an oral testosterone replacement therapy (TRT) powered by Kyzatrex, which is approved by the Food and Drug Administration, a US health agency. Kyzatrex is an oral formulation of testosterone undecanoate intended to treat adult males with conditions associated with hypogonadism. This development represents a significant advancement in treating adult males suffering from hypogonadism, a condition marked by low testosterone levels, positioning PRIME as a convenient option for individuals seeking effective TRT alternatives.

There is a growing emphasis on testosterone cypionate injections among major companies in the testosterone replacement therapy market. Testosterone cypionate is a synthetic form of the male sex hormone testosterone and is commonly prescribed as part of testosterone replacement therapy to address conditions associated with testosterone deficiency. In April 2023, Xiromed LLC launched Testosterone Cypionate Injection (USP), providing a new option for males with low testosterone or related conditions such as erectile dysfunction or hypogonadism. This injectable form of testosterone is recognized for its effectiveness in restoring testosterone levels to a healthy range, making it a valuable solution for hormone replacement therapy, especially for individuals experiencing symptoms of testosterone deficiency.

In October 2022, Tolmar Pharmaceuticals Inc., a US-based pharmaceutical company specializing in testosterone therapy, acquired Clarus Therapeutics Inc. for an undisclosed amount. This acquisition is intended to enhance Tolmar Pharmaceuticals Inc.'s portfolio in urology and men’s health by incorporating JATENZO, a testosterone replacement therapy developed by Clarus Therapeutics Inc. Clarus Therapeutics Inc. is a US-based company engaged in testosterone replacement therapy.

Major companies operating in the testosterone replacement therapy market include AbbVie Inc., Acerus Pharmaceuticals Corporation, Antares Pharma Inc., Bayer Aktiengesellschaft, BioTE Medical LLC, Clarus Therapeutics Inc., Eli Lilly and Company, Endo International plc, Pfizer Inc., Teva Pharmaceutical Industries Limited, Acrux Limited, Actiza Pharmaceutical Inc., Aytu BioPharma Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, Ferring Pharmaceuticals Holdings S.A., Mylan N.V., Bausch Health Companies Inc., Allergan plc, Sandoz International GmbH, Perrigo Company plc, Besins Healthcare.

North America was the largest region in the testosterone replacement therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the testosterone replacement therapy market report during the forecast period. The regions covered in the testosterone replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the testosterone replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Testosterone replacement therapy is a hormonal treatment method utilized to address low testosterone (T) levels in males, commonly associated with aging or certain medical conditions.

The primary types of testosterone replacement therapy include oral formulations, implants, gels or creams, patches, buccal adhesives, parenteral administration, and other delivery methods. Oral administration involves intake through the mouth via tablets, capsules, syrups, or similar forms. Low testosterone indications encompass conditions such as hypogonadism, autoimmune disorders, genetic abnormalities, sex organ surgeries, and other related issues. Various active ingredients are employed in treating such conditions, including testosterone, methyl testosterone, testosterone undecanoate, testosterone enanthate, and testosterone cypionate. These therapies are administered by various end-users, including hospitals, clinics, and other healthcare facilities.

The testosterone replacement therapy market research report is one of a series of new reports that provides testosterone replacement therapy market statistics, including testosterone replacement therapy industry global market size, regional shares, competitors with a testosterone replacement therapy market share, detailed testosterone replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the testosterone replacement therapy industry. This testosterone replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The testosterone replacement therapy market includes revenues earned by entities by providing hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy to treat low testosterone deficiency. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.